# Human rhinovirus detection in the lower respiratory tract of hematopoietic cell transplant recipients: association with mortality

Sachiko Seo,[1,2] Alpana Waghmare,[1,3,4] Emily M Scott,[5] Hu Xie,[6] Jane M Kuypers,[1,7] Robert C. Hackman,[1] Angela P. Campbell,[1,3,4,*] Su-Mi Choi,[8] Wendy M. Leisenring,[6] Keith R. Jerome,[1,7] Janet A. Englund[1,3,4] and Michael Boeckh[1,6,9]

[1]Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; [2]Department of Hematology and Oncology, National Cancer Research Center East, Chiba, Japan; [3]Department of Pediatrics, University of Washington, Seattle, WA, USA; [4]Pediatric Infectious Disease Division, Seattle Children's Hospital, WA, USA; [5]School of Medicine, University of Washington, Seattle, WA, USA; [6]Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; [7]Department of Laboratory Medicine, University of Washington, Seattle, WA, USA; [8]Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea and [9]Department of Medicine, University of Washington, Seattle, WA, USA

*Present affiliation: Centers for Disease Control and Prevention, Atlanta, GA, USA

| Supplemental Table 1. Risk factors for mortality from all causes or respiratory failure by day 90 after HRV LRI (N=128) | | | | | | |
|---|---|---|---|---|---|---|
| | **Univariable analysis** | | | **Multivariable analysis** | | |
| | **HR** | **95% CI** | ***P* Value** | **HR** | **95% CI** | ***P* Value** |
| **Overall mortality** | | | | | | |
| **Lymphocyte count at diagnosis** | | | | | | |
| > 300 cells/µL | 1.00 | | | 1.00 | | |
| ≤ 300 cells/µL | 2.70 | 1.49-4.76 | 0.001 | 1.96 | 1.05-3.66 | 0.036 |
| **Monocyte count at diagnosis** | | | | | | |
| > 300 cells/µL | 1.00 | | | 1.00 | | |
| ≤ 300 cells/µL | 2.44 | 1.33-4.55 | 0.004 | 1.49 | 0.75-3.03 | 0.26 |
| **LRI symptoms at diagnosis** | | | | | | |
| No | 1.00 | | | 1.00 | | |
| Yes | 3.03 | 1.37-6.74 | 0.006 | 1.42 | 0.50-4.08 | 0.51 |
| **Oxygen use at diagnosis** | | | | | | |
| No | 1.00 | | | 1.00 | | |
| Yes | 2.94 | 1.54-5.62 | 0.001 | 2.87 | 1.25-6.60 | 0.013 |
| Mechanical ventilation | 10.3 | 4.82-22.0 | <0.001 | | | |
| **Steroid dose before diagnosis*** | | | | | | |
| No | 1.00 | | | | | |
| < 1 mg/kg | 0.82 | 0.41-1.64 | 0.58 | 1.00 | | |
| ≥ 1 mg/kg | 3.69 | 1.93-7.03 | <0.001 | 1.96 | 1.04-3.69 | 0.038 |
| **Steroid dose after diagnosis#** | | | | | | |
| No | 1.00 | | | 1.00 | | |
| < 1 mg/kg | 1.39 | 0.64-3.0 | 0.40 | | | |

| | | | | | | |
|---|---|---|---|---|---|---|
| | | 1 | | | | |
| ≥ 1 mg/kg | 4.92 | 2.39-10.1 | <0.001 | 2.55 | 1.39-4.69 | 0.003 |
| **Ct value at diagnosis** [†] | 0.99 | 0.95-1.04 | 0.70 | | | |
| **Mortality from respiratory failure** | | | | | | |
| **Lymphocyte count at diagnosis** | | | | | | |
| > 300 cells/µL | 1.00 | | | 1.00 | | |
| ≤ 300 cells/µL | 2.50 | 1.30-4.76 | 0.006 | 1.87 | 0.93-3.75 | 0.08 |
| **Monocyte count at diagnosis** | | | | | | |
| > 300 cells/µL | 1.00 | | | 1.00 | | |
| ≤ 300 cells/µL | 2.44 | 1.22-4.76 | 0.012 | 1.12 | 0.54-2.34 | 0.75 |
| **LRI symptoms at diagnosis** | | | | | | |
| No | 1.00 | | | 1.00 | | |
| Yes | 4.28 | 1.52-12.0 | 0.006 | 2.40 | 0.70-8.26 | 0.16 |
| **Oxygen use at diagnosis** | | | | | | |
| No | 1.00 | | | 1.00 | | |
| Yes | 2.72 | 1.31-5.66 | 0.007 | 2.09 | 0.89-4.93 | 0.09 |
| Mechanical ventilation | 10.3 | 4.47-23.8 | <0.001 | | | |
| **Steroid dose before diagnosis*** | | | | | | |
| No | 1.00 | | | 1.00 | | |
| < 1 mg/kg | 1.22 | 0.55-2.67 | 0.63 | | | |
| ≥ 1 mg/kg | 4.65 | 2.18-9.92 | <0.001 | 2.25 | 1.11-4.58 | 0.025 |
| **Steroid dose after diagnosis**[#] | | | | | | |
| No | 1.00 | | | 1.00 | | |
| < 1 mg/kg | 1.68 | 0.66-4.3 | 0.28 | | | |

| | | 0 | | | | |
|---|---|---|---|---|---|---|
| ≥ 1 mg/kg | 6.90 | 2.90-16.4 | <0.001 | 2.77 | 1.39-5.52 | 0.004 |
| **Ct value at diagnosis** [†] | 0.99 | 0.94-1.04 | 0.68 | | | |

**\*** Peak steroid dose was recorded from the period within two weeks prior to LRI.

**#** Peak steroid dose after LRI diagnosis was recorded from within two weeks after the diagnosis. These variables are analyzed as time-dependent.

[†] This analysis was performed as a continuous variable.

All variables in Table 1 were used for the univariable analysis. Only variables with p < 0.05 are shown in this table. Ct value was shown regardless of p values.

Abbreviations; HRV: human rhinovirus, LRI: lower respiratory tract infection, Ct: cycle threshold